Adam Steensberg

“And as Ceylon Pharma is a Danish-founded company, we've been 27 years in the making, and we are on a journey towards becoming a leader in metabolic health.”

“In the first half of 2026, we delivered on the key objectives we set out at the start of the year and drew significant progress across our pipeline. I'm pleased to walk through those accomplishments today.”

“Absolutely, and as you said, I've just spent almost a week around at ADA and it was a really, you can say, positive experience coming out of ADA and kicking off Friday with a symposium on Amelyn and really starting to change the conversations from how we get to the maximum tolerated doses more towards how do you get…”

“Okay, so I think, look, what's remarkable at ADA is not only petrol inside, but also so the server-to-tide data readouts. And if you think about a company our size, to have two practice-changing medicines read out at the same conference is pretty remarkable.”

“2026 so far has been marked by a defining milestones for seal and pharma. At our Capital Markets Day in December, we announced our ambition to become a leader in obesity and metabolic health and made several commitments with the launch of our strategy, Metabolic Frontier 2030.”